拉米夫定联合微波消融治疗原发性肝癌40例  

Lamivudine therapy after percutaneous microwave coagultion therapy for patients with primary hepatocellular carcinoma complicated with hepatitis B virus:an analysis of 40 cases

作　　者：彭齐荣[1] 肖必[1] 程涛[1] 谭永才[1] 李灼亮[1] 余宙耀[1] 

机构地区：[1]解放军第458医院全军肝病中心,广东广州510602

出　　处：《现代肿瘤医学》2010年第4期755-757,共3页Journal of Modern Oncology

摘　　要：目的:探讨拉米夫定联合经皮微波消融(PMCT)治疗乙肝病毒DNA阳性的肝细胞癌(HCC)患者的疗效。方法:乙肝病毒DNA阳性的原发性肝癌(PHC)患者40例为研究组,同时接受PMCT+拉米夫定,单纯PMCT治疗的40例同类患者为对照组,观察比较两组患者乙肝病毒DNA定量和ALT水平。结果:治疗1周及2周时,两组患者乙肝病毒DNA定量、ALT值比较无显著差异(P>0.05),治疗4周时,研究组乙肝病毒DNA量和ALT水平明显小于对照组(P<0.05)。结论:拉米夫定联合PMCT治疗乙肝病毒DNA阳性的HCC患者,可抑制乙型肝炎病毒复制,减轻肝脏炎症,保护患者肝功能。Objective：To evaluate therapeutic effects of lamivudine and percutaneous microwave coagultion therapy（PMCT） in patients with primary hepatocellular carcinoma（PHC） complicated with hepatitis B virus（HBV）.Methods：Treatment group was treated by PMCT ＋ lamivudine（40 cases）,control group was treated by PMCT（40 cases）.Results：There were no diffences in DNA and ALT level between two groups after 1 and 2 weeks（P〉0.05）,but was diffent after 4 weeks（P 〈0.05）.Conclusion：Lamivudine therapy after PMCT can inhibit copy of HBV and protect liver function of the patients.

关 键 词：拉米夫定 原发性肝癌 乙型肝炎病毒 经皮微波消融术 

分 类 号：R735.7[医药卫生—肿瘤]